Icotinib Hydrochloride - CAS# 1204313-51-8 Size:Solid 10 mg InChi: InChI=1S/C27H30O7/c1-13-15(14-7-9-32-12-14)10-16-20(13)27(4)17(11-19(29)31-5)26(3)18(28)6-8-25(2)22(26)21(23(27)33-16)34-24(25)30/h6-9

InChi: InChI=1S/C27H30O7/c1-13-15(14-7-9-32-12-14)10-16-20(13)27(4)17(11-19(29)31-5)26(3)18(28)6-8-25(2)22(26)21(23(27)33-16)34-24(25)30/h6-9

Chemical Name: 1-(quinoxalin-6-ylcarbonyl)piperidine

InChiKey: XOIQMTLWECTKJL-WMQCWNTASA-M

A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery

Solubility: DMSO 85 mg/mL (200

Icotinib Hydrochloride - CAS# 1204313-51-8 Size:Solid 10 mg InChi: InChI=1S/C27H30O7/c1-13-15(14-7-9-32-12-14)10-16-20(13)27(4)17(11-19(29)31-5)26(3)18(28)6-8-25(2)22(26)21(23(27)33-16)34-24(25)30/h6-9Icotinib, also known as BPI 2009, is an orally available quinazoline based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, is upregulated in a variety of cancer cell